United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Home Use

Core Viewpoint - Biomerica, Inc. has received approval from the UAE Ministry of Health and Prevention for its Fortel® Ulcer Test for home use, enhancing access to diagnostic tools for H. pylori infections, a major cause of gastric diseases in the region [1][4]. Product Overview - The Fortel® Ulcer Test is a rapid 10-minute diagnostic test that detects antibodies to Helicobacter pylori, which is linked to peptic ulcers, dyspepsia, and a significant number of gastric cancer cases [2][8]. - The test allows individuals in the UAE to self-administer it at home, promoting convenience and privacy [2]. Health Impact - Approximately 41% of the UAE population is affected by H. pylori, with untreated infections leading to serious complications in up to 20% of cases, including peptic ulcers and gastric malignancies [3]. - H. pylori is associated with about 80% of gastric cancer cases and is classified as a Class 1 carcinogen by the World Health Organization [3][8]. Market Strategy - Biomerica is collaborating with local distributors and healthcare providers to make the Fortel® Ulcer Test available through pharmacies, clinics, and online platforms, thereby expanding its presence in the Middle East [4]. - The company aims to improve patient outcomes through early detection and affordable diagnostic solutions, as exemplified by the Fortel® Ulcer Test [5]. Company Background - Biomerica, Inc. is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products for point-of-care use, particularly in gastrointestinal and inflammatory diseases [6].